Xbrane Biopharma AB (STO:XBRANE), a commercial phase Swedish biopharmaceutical company that develops and produces biosimilars, announced on Wednesday the filing of three patent applications that further strengthen its proprietary low-cost biosimilar platform technology.
These three patent applications have been filed with the Swedish patent and Registration Office (PRV). They relate to novel methods of using signal peptides to enhance the production yield and thereby lower the production cost of recombinant proteins.
The patents cover new inventions that further strengthen Xbrane's platform, the company said.
According to Xbrane, it bases the development of its biosimilars on a patented platform technology providing higher yields and thereby lower production cost of high-quality recombinant proteins compared to standard systems. Xbrane works actively with its team of scientists to innovate around the platform and thereby further strengthen its competitive advantage as a biosimilar developer.
The company's ambition is to follow-up the patent applications with international patent applications with focus on commercially important jurisdictions such as US, Europe, Japan and China.
These recently filed patent applications are jointly owned, at equal shares, by Xbrane and CloneOpt, a Stockholm University spin-out. The applications are among several planned patent applications which the newly established IP department of Xbrane will file either alone or jointly with other companies to build a broader IP portfolio around its platform technology.
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001
Ascletis doses first US participants in ASC30 Phase IIa study for obesity treatment
Jacobio's JAB-8263 Phase I/II Clinical Trial IND application receives Chinese regulatory approval